These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34511698)

  • 1. Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness.
    Faisal HMN; Katti KS; Katti DR
    Chem Phys; 2021 Nov; 551():111353. PubMed ID: 34511698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
    Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
    Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study.
    Dehury B; Raina V; Misra N; Suar M
    J Biomol Struct Dyn; 2021 Nov; 39(18):7231-7245. PubMed ID: 32762417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
    Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
    BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study.
    Yang Y; Zhang Y; Qu Y; Zhang C; Liu XW; Zhao M; Mu Y; Li W
    Nanoscale; 2021 May; 13(20):9364-9370. PubMed ID: 33999091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Development of SARS-CoV-2 Spike Interactors.
    Squeglia F; Romano M; Esposito L; Barra G; Campiglia P; Sala M; Scala MC; Ruggiero A; Berisio R
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    bioRxiv; 2020 Jul; ():. PubMed ID: 32766576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor.
    Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S
    Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
    Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
    Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor.
    Giordano D; De Masi L; Argenio MA; Facchiano A
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.